Interaction of Apelin and Angiotensin in the Human Forearm Circulation

Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00901888

Enrollment

Registered

2009-05-14

Start date

2009-04-30

Completion date

2010-05-31

Last updated

2010-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Disease, Vasodilation

Keywords

Renin Angiotensin System

Brief summary

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease. Angiotensin has a powerful ability to cause blood vessels constrict and reduces their diameter. One of the actions of apelin is to cause blood vessels to relax and the investigators specifically wish test the hypothesis that apelin will cause blood vessels constricted by angiotensin II to relax.

Interventions

DRUGApelin infusion

Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.

DRUGSodium nitroprusside infusion

Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* \> 18 years old

Exclusion criteria

* Lack of informed consent * Age \< 18 years, * Current involvement in other research studies, * Systolic blood pressure \>190 mmHg or \<100 mmHg * Malignant arrhythmias * Renal or hepatic failure * Haemodynamically significant aortic stenosis * Severe or significant co morbidity * Women of childbearing potential. * Any regular medication * Previous history of any cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Change in apelin mediated forearm blood flow	12 months

Secondary

Measure	Time frame
Change in local and systemic plasma apelin concentration in response angiotensin II infusion	12 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026